The state of Florida currently has 37 active clinical trials seeking participants for Asthma research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
NCT03953300
Recruiting
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/14/2025
Locations: Research Site, Jacksonville, Florida +2 locations
Conditions: Asthma
Register for Updates
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
NCT06572228
Recruiting
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms while taking their current asthma medication. The aim of the study is to see which regimen is more effective: taking dupilumab with an inhaled asthma medication or only taking a higher dose of the inhaled asthma medicati... Read More
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
07/11/2025
Locations: St Francis Medical Institute, Clearwater, Florida +2 locations
Conditions: Asthma
Register for Updates
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT06979323
Recruiting
Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably. The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: GSK Investigational Site, Plantation, Florida
Conditions: Asthma
Register for Updates
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289
Recruiting
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA.
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
06/24/2025
Locations: Research Site, Cape Coral, Florida +6 locations
Conditions: Eosinophilic Asthma
Register for Updates
Azithromycin for Critical Asthma - Pediatrics
NCT06223828
Recruiting
The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
06/18/2025
Locations: Johns Hopkins All Children's Hospital, Saint Petersburg, Florida
Conditions: Pediatric Asthma, Critical Illness
Register for Updates
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
NCT06529419
Recruiting
A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting Ξ²2-agonist (LABA).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/16/2025
Locations: Research Site, DeBary, Florida +6 locations
Conditions: Asthma
Register for Updates
Asthma and Technology in Emerging African American Adults
NCT05445583
Recruiting
The purpose of the ATHENA Project is to test a mobile health intervention to help African American young adults better manage their asthma. The program has four components: 1) a web-based, mobile asthma program delivered to participants' mobile device, 2) meetings with an asthma nurse via video conference, 3) text messaging, and 4) physical activity tracking. Participants will be randomly assigned to one or more of these components to better meet the needs of young adults with asthma.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
06/10/2025
Locations: Florida State University, Tallahassee, Florida
Conditions: Asthma
Register for Updates
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
NCT05757102
Recruiting
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/04/2025
Locations: GSK Investigational Site, Aventura, Florida +3 locations
Conditions: Asthma
Register for Updates
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053
Recruiting
This study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma. The study will be conducted in two parts - Part A (dose finding phase) and Part B (extended dosing phase). Part A will assess the lung function, asthma control, participant safety and certain markers... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/08/2025
Locations: GSK Investigational Site, Miami, Florida
Conditions: Asthma
Register for Updates
Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)
NCT06940141
Recruiting
This is a Phase 2, randomized, multicenter study in adult and adolescent participants with asthma and type 2 inflammation
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
05/07/2025
Locations: Synergy Healthcare, Bradenton, Florida
Conditions: Asthma Acute
Register for Updates
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404
Recruiting
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
03/11/2025
Locations: University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida
Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Hemophilia, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Register for Updates
Innate Immunity in Allergic Asthma
NCT06068335
Recruiting
The purpose of this study is to determine whether a potential type 2 signature, obtained through stimulation of cell lines with various allergens in vitro, correlates with an allergic or asthmatic disease state ex vivo. This type 2 signature will be multi-hierarchical in nature and will be comprised cell surface receptor expression, pathway activation, and gene upregulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: University of Central Florida, Orlando, Florida
Conditions: Asthma
Register for Updates